dc.contributor.author | Sørbye, Sveinung Wergeland | |
dc.contributor.author | Fismen, Silje | |
dc.contributor.author | Gutteberg, Tore Jarl | |
dc.contributor.author | Mortensen, Elin Synnøve | |
dc.contributor.author | Skjeldestad, Finn Egil | |
dc.date.accessioned | 2013-04-26T09:20:03Z | |
dc.date.available | 2013-04-26T09:20:03Z | |
dc.date.issued | 2013 | |
dc.description.abstract | Background: In delayed HPV triage women with atypical squamous cells of uncertain significance (ASC-US) cytology are retested after 6-12 months in order to decide whether they should be referred for colposcopy, further follow-up cytology or routine screening in three years. Triage using a specific HPV E6/E7 mRNA test may reduce referrals for colposcopy of women with ASC-US cytology compared to HPV DNA testing. We explored whether HPV mRNA triaging could reduce the time from ASC-US index cytology to biopsy compared with repeat cytology, and whether the positive predictive value (PPV) of the HPV mRNA test for high grade cervical intraepithelial neoplasia (CIN2+) was comparable with the PPV of repeat cytology. Material and methods: We used repeat cytology and the HPV mRNA test PreTect HPV-Proofer, which detects E6/E7 mRNA from HPV subtypes 16, 18, 31, 33 and 45, in the triage of women with ASC-US. We included all women from the two northernmost counties of Norway with a first ASC-US cytology during the period 2004-2008. Two triage methods were evaluated 1) only repeat cytology (n=964) and 2) both HPV mRNA testing and cytology (n=542). Histologically confirmed CIN2+ was the study endpoint. Results: Among 1506 women with an ASC-US index cytology, 59 women (3.9%) had biopsy taken, of whom 49 women had CIN2+ (PPV 83.1%). The mean time from index ASC-US cytology until the case was resolved (biopsy or return to screening) was 10.6 months in the repeat cytology group and 7.3 months in the HPV group (P<0.001). Of the 964 women in the group with repeat cytology only, 35 women (3.6%) had biopsy and 30 had CIN2+ (PPV 85.7%). Of the 542 women in the group with both HPV test and cytology, 24 women (4.4%) had biopsy and 19 had CIN2+ (PPV 79.2%). Conclusion: In triage of women with ASC-US, the HPV mRNA test significantly reduced the time from the first abnormal cytology until biopsy and had predictive values comparable with those of repeat cytology. | en |
dc.identifier.citation | Current Pharmaceutical Design (2013), vol.19 (8):1401-1405 | en |
dc.identifier.cristinID | FRIDAID 949637 | |
dc.identifier.doi | http://dx.doi.org/10.2174/138161213804805487 | |
dc.identifier.issn | 1381-6128 | |
dc.identifier.uri | https://hdl.handle.net/10037/5132 | |
dc.identifier.urn | URN:NBN:no-uit_munin_4844 | |
dc.language.iso | eng | en |
dc.publisher | Bentham Science Publishers | en |
dc.rights.accessRights | openAccess | |
dc.subject | VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Gynecology and obstetrics: 756 | en |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gynekologi og obstetrikk: 756 | en |
dc.subject | VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 | en |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 | en |
dc.title | HPV mRNA testing in triage of women with ASC-US cytology may reduce the time for CIN2+ diagnosis compared with repeat cytology. | en |
dc.type | Journal article | en |
dc.type | Tidsskriftartikkel | en |
dc.type | Peer reviewed | en |